The world's scientific and social network for malaria professionals
Subscribe to free Newsletter | 10481 malaria professionals are enjoying the free benefits of MalariaWorld today

Scientific Articles

Special Focus Review: From the circumsporozoite protein to the RTS,S/AS candidate vaccine

October 25, 2009 - 16:43 -- Ingeborg van Schayk
Tags: 
Author(s): 
Joe Cohen, Victor Nussenzweig, Johan Vekemans and Amanda Leach
Reference: 
Human Vaccines, Volume 6, Issue 1, January 2010

The RTS,S/AS01E malaria vaccine candidate has recently entered phase 3 testing. Reaching this important milestone is the culmination of more than 20 years of research and development by GlaxoSmithKline and partners and collaborators. The vaccine has been developed to protect young children and infants living in sub-Saharan Africa against clinical and severe disease caused by Plasmodium falciparum infection.

Continent: 
Medical Condition: 
Medical Treatment: 

Association of Malaria-Induced Murine Pregnancy Failure with Robust Peripheral and Placental Cytokine Responses

October 25, 2009 - 16:36 -- Bart G.J. Knols
Author(s): 
Jayakumar Poovassery and Julie M. Moore
Reference: 
Infect. Immun. 2009;77 4998-5006

Plasmodium chabaudi AS infection during early pregnancy results in midgestational embryonic loss in naive C57BL/6 mice. To define the immunopathogenesis of this malaria-induced pregnancy compromise, cytokine production in plasma, spleen, and placenta cell culture supernatants during the first 11 days of infection and gestation was studied. These results suggest that systemic and placenta-level proinflammatory antimalarial immune responses, in the absence of adequate and sustained counterregulatory mechanisms, contribute to pregnancy loss in this model.

 

Technology: 
Medical Condition: 
Medical Treatment: 

Current status of Plasmodium vivax vaccine

October 25, 2009 - 16:36 -- Ingeborg van Schayk
Tags: 
Author(s): 
Myriam Arévalo-Herrera, Chetan Chitnis and Sócrates Herrera
Reference: 
Human Vaccines, Volume 6, Issue 1, January 2010

The increasing P. vivax drug resistance and reports of severe and lethal cases, the relapsing parasite behavior and the existence of Plasmodium spp co-infections must prompt more investment and greater efforts for the development of P. vivax vaccine.

Medical Treatment: 

Development of a metabolically active, non-replicating sporozoite vaccine to prevent Plasmodium falciparum malaria

October 25, 2009 - 16:33 -- Bart G.J. Knols
Author(s): 
Stephen L. Hoffman et al.
Reference: 
Human Vaccines, Volume 6, Issue 1, January 2010

 No abstract

Medical Condition: 
Medical Treatment: 

Alternative approaches to vaccine delivery

October 25, 2009 - 16:31 -- Ingeborg van Schayk
Author(s): 
Lina Wang, Charles Ma and Ross L. Coppel
Reference: 
Human Vaccines, Volume 6, Issue 1, January 2010

Subunit vaccines under development for malaria utilise a limited number of approaches to delivery. 

Therefore, along with the efforts to advance the most promising vaccine formulations through the development pipeline, research is taking place into alternative methods for cheaper vaccine production and easy administration. This chapter will discuss some of these approaches, including transgenic plants and mammals as bioreactors for low cost vaccine production and alternative routes of vaccine delivery such as mucosal immunization.

Medical Treatment: 

Whole parasite blood stage malaria vaccines: A convergence of evidence

October 25, 2009 - 16:29 -- Bart G.J. Knols
Author(s): 
James S McCarthy and Michael F. Good
Reference: 
Human Vaccines, Volume 6, Issue 1, January 2010

In this review previous studies in rodents and primates of whole killed and attenuated blood stage vaccines, and recent work on the effect of genetically attenuated parasites on immunity in rodent models of blood stage immunity are discussed. The relationship between these findings and what is now known about protective immunity in human populations, specifically against the blood stages of the parasite lifecycle is discussed and recent findings from human experimental infection are be reviewed.

Technology: 
Region: 
Medical Condition: 

Prime-boost vectored malaria vaccines: Progress and prospects

October 25, 2009 - 16:25 -- Ingeborg van Schayk
Author(s): 
Adrian V. S. Hill, Arturo Reyes-Sandoval, Geraldine O’Hara, Katie Ewer, Alison Lawrie, Anna Goodman, Alfredo Nicosia, Antonella Folgori, Stefano Colloca, Riccardo Cortese, Sarah C. Gilbert and Simon Draper
Reference: 
Human Vaccines, Volume 6, Issue 1, January 2010

The difficulty of inducing protective immunity through antibodies against sporozoites led to efforts to assess vectored vaccines as a means of inducing protective T cell immunity against the malaria liver-stage parasite. Although DNA vectored vaccines used alone were poorly immunogenic and not protective, high levels of parasite clearance in the liver has been achieved with viral vectored vaccines used in heterologous prime-boost regimes.

Medical Condition: 
Medical Treatment: 

Vaccines against malaria: Perspectives from Papua New Guinea

October 25, 2009 - 16:21 -- Bart G.J. Knols
Author(s): 
Ivo Mueller, Blaise Genton, Inoni Betuela and Michael P. Alpers
Reference: 
Human Vaccines, Volume 6, Issue 1, January 2010

Despite its small population and isolate location Papua New Guinea (PNG) with a malaria burden comparable to sub-Saharan Africa, its intense transmission of all 4 human Plasmodium species and an unrivalled combination of environmental and human variation offers unique perspectives on malaria vaccines.

Technology: 
Continent: 
Medical Condition: 
Medical Treatment: 

Guidelines and considerations for testing malaria vaccines in pregnant women

October 25, 2009 - 16:20 -- Ingeborg van Schayk
Tags: 
Author(s): 
Clara Menendez and Pedro Alonso
Reference: 
Human Vaccines, Volume 6, Issue 1, January 2010

Important progress has been made in the last years especially in sub-Saharan Africa, with the introduction of strategies to prevent malaria in pregnancy consisting of intermittent preventive treatment and insecticide treated nets. However, their coverage is still unacceptably low and malaria continues to demand a huge toll on pregnant women and their newborns. Thus, there is a need to explore other preventive strategies such as a vaccine against malaria, which combined with the current tools would maximise the protection efficacy.

Person: 
Medical Treatment: 

Special Focus Review: European malaria vaccine initiative: Portfolio and perspectives for the future

October 25, 2009 - 16:12 -- Ingeborg van Schayk
Tags: 
Author(s): 
Egeruan Babatunde Imoukhuede, Roland Ventura, Nathalie Imbault, Harry van Schooten and Odile Leroy
Reference: 
Human Vaccines, Volume 6, Issue 1, January 2010

Over the past ten years, EMVI has continually strived to maintain its main goal of accelerating the development of candidate malaria vaccines by facilitating the translational gap between promising experimental malaria vaccines and subsequent clinical trials in Europe and in Africa. By stimulating collaboration, cooperation, networking and joint integrated activities across various fields of research and diseases, and by facilitating the federation of research infrastructures, EMVI is acting today as a catalyst for tomorrow’s vaccines.

Medical Treatment: 

Pages

Subscribe to Scientific Articles